Star Cement (540575) Q4 16/17 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 16/17 earnings summary
19 Oct, 2026Executive summary
FY2016-17 held up despite demonetisation and a weak cement market; leadership in North Eastern India was maintained, while sales expanded in West Bengal and Bihar.
Consolidated PAT rose to ₹171.63 crore from ₹134.04 crore; EBITDA was ₹410.97 crore, with margin reported at 23.78%.
Financial highlights
Consolidated net revenue was ₹1,728.00 crore versus ₹1,715.03 crore in FY2015-16; gross revenue was ₹1,752.04 crore.
Consolidated EBITDA was ₹410.97 crore versus ₹400.69 crore; PBT was ₹191.80 crore versus ₹145.30 crore.
Consolidated PAT was ₹171.63 crore versus ₹134.04 crore; EPS was ₹4.09 versus ₹3.20.
Operating cash flow reached ₹306.96 crore, compared with ₹97.03 crore in FY2015-16; investing cash outflow was ₹90.28 crore.
Outlook and guidance
Management expected further operational improvement in FY2017-18, with cement capacity augmentation through de-bottlenecking aimed at lower costs.
Market presence was to deepen tehsil- and panchayat-wise; management viewed operating leverage and brand strength as supports for growth, calling FY2017-18 a potential watershed year.
Capacity was expected to support 10-15% growth over the next two years; this was a stated outlook, not a reported result.
Latest events from Star Cement
- Record profits and sharp debt reduction set the stage for capacity-led growth.540575
Q4 17/18 - Revenue and cement volumes grew, but subsidy expiry cut earnings as expansion plans advanced.540575
Q4 18/19 - Higher volumes and earnings set up expansion, tempered by cost and litigation risks.540575
Q4 21/22 - Volume growth and low gearing offset by weaker profits and uncertain FY21 demand.540575
Q4 19/20 - FY21 resilience, a 20.98% EBITDA margin and 2-MTPA Siliguri expansion.540575
Q4 20/21 - Higher volumes lifted FY23 results as major capacity expansion advanced.540575
Q4 22/23 - Q1 FY27 revenue rose but margins fell; expansion and H2 recovery expected as costs ease.540575
Q1 26/27 - Strong Q3 growth, interim dividend, and promoter reclassification highlight performance.540575
Q3 25/26 - Record Q4 sales, EBITDA, and PAT with strong growth, incentives, and capacity expansion.540575
Q4 24/25